S&P 500   4,064.73 (-0.38%)
DOW   34,270.73 (-0.92%)
QQQ   292.19 (-0.40%)
AAPL   147.15 (-0.59%)
MSFT   252.34 (-1.10%)
META   119.19 (+0.92%)
GOOGL   100.66 (-0.33%)
AMZN   95.92 (-0.64%)
TSLA   193.85 (-0.44%)
NVDA   169.60 (+0.22%)
NIO   12.28 (-3.91%)
BABA   85.87 (-1.93%)
AMD   76.54 (-1.40%)
T   19.17 (-0.57%)
MU   55.46 (-3.80%)
CGC   3.67 (+1.38%)
F   14.14 (+1.73%)
GE   85.52 (-0.52%)
DIS   97.87 (+0.00%)
AMC   8.27 (+14.38%)
PYPL   78.35 (-0.08%)
PFE   50.49 (+0.72%)
NFLX   315.12 (+3.14%)
S&P 500   4,064.73 (-0.38%)
DOW   34,270.73 (-0.92%)
QQQ   292.19 (-0.40%)
AAPL   147.15 (-0.59%)
MSFT   252.34 (-1.10%)
META   119.19 (+0.92%)
GOOGL   100.66 (-0.33%)
AMZN   95.92 (-0.64%)
TSLA   193.85 (-0.44%)
NVDA   169.60 (+0.22%)
NIO   12.28 (-3.91%)
BABA   85.87 (-1.93%)
AMD   76.54 (-1.40%)
T   19.17 (-0.57%)
MU   55.46 (-3.80%)
CGC   3.67 (+1.38%)
F   14.14 (+1.73%)
GE   85.52 (-0.52%)
DIS   97.87 (+0.00%)
AMC   8.27 (+14.38%)
PYPL   78.35 (-0.08%)
PFE   50.49 (+0.72%)
NFLX   315.12 (+3.14%)
S&P 500   4,064.73 (-0.38%)
DOW   34,270.73 (-0.92%)
QQQ   292.19 (-0.40%)
AAPL   147.15 (-0.59%)
MSFT   252.34 (-1.10%)
META   119.19 (+0.92%)
GOOGL   100.66 (-0.33%)
AMZN   95.92 (-0.64%)
TSLA   193.85 (-0.44%)
NVDA   169.60 (+0.22%)
NIO   12.28 (-3.91%)
BABA   85.87 (-1.93%)
AMD   76.54 (-1.40%)
T   19.17 (-0.57%)
MU   55.46 (-3.80%)
CGC   3.67 (+1.38%)
F   14.14 (+1.73%)
GE   85.52 (-0.52%)
DIS   97.87 (+0.00%)
AMC   8.27 (+14.38%)
PYPL   78.35 (-0.08%)
PFE   50.49 (+0.72%)
NFLX   315.12 (+3.14%)
S&P 500   4,064.73 (-0.38%)
DOW   34,270.73 (-0.92%)
QQQ   292.19 (-0.40%)
AAPL   147.15 (-0.59%)
MSFT   252.34 (-1.10%)
META   119.19 (+0.92%)
GOOGL   100.66 (-0.33%)
AMZN   95.92 (-0.64%)
TSLA   193.85 (-0.44%)
NVDA   169.60 (+0.22%)
NIO   12.28 (-3.91%)
BABA   85.87 (-1.93%)
AMD   76.54 (-1.40%)
T   19.17 (-0.57%)
MU   55.46 (-3.80%)
CGC   3.67 (+1.38%)
F   14.14 (+1.73%)
GE   85.52 (-0.52%)
DIS   97.87 (+0.00%)
AMC   8.27 (+14.38%)
PYPL   78.35 (-0.08%)
PFE   50.49 (+0.72%)
NFLX   315.12 (+3.14%)
Positive News Sentiment  
NASDAQ:TNDM

Tandem Diabetes Care - TNDM Stock Forecast, Price & News

$41.64
-0.41 (-0.98%)
(As of 12/1/2022 12:03 PM ET)
Add
Compare
Today's Range
$41.14
▼
$42.44
50-Day Range
$35.72
▼
$56.15
52-Week Range
$33.51
▼
$155.86
Volume
14,505 shs
Average Volume
1.58 million shs
Market Capitalization
$2.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.93

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
86.0% Upside
$76.93 Price Target
Short Interest
Healthy
8.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.51mentions of Tandem Diabetes Care in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.76) to ($0.48) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

51st out of 1,047 stocks

Surgical & Medical Instruments Industry

6th out of 104 stocks

See Top Rated MarketRank™ Stocks Here
TNDM stock logo

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Stock News Headlines

November 24, 2022 | finance.yahoo.com
Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 49% Undervaluation?
November 23, 2022 | americanbankingnews.com
Analysts Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Target Price at $73.62
November 16, 2022 | finance.yahoo.com
Tandem Diabetes Care Earns Great Place to Work Certification™
November 10, 2022 | finance.yahoo.com
Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology
November 7, 2022 | finance.yahoo.com
Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut
November 5, 2022 | markets.businessinsider.com
Barclays Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
November 3, 2022 | marketwatch.com
Tandem Diabetes Shares Hit Fresh 52-Week Low After 3Q Update >TNDM
November 3, 2022 | finance.yahoo.com
Tandem Diabetes Shares Slump After Dismal Annual Outlook
November 3, 2022 | investing.com
Tandem Diabetes Care PT Lowered to $70 at Piper Sandler
November 2, 2022 | finance.yahoo.com
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Misses Revenue Estimates
November 2, 2022 | finance.yahoo.com
Tandem Diabetes Care Announces Third Quarter 2022 Financial Results and Updated Full Year 2022 Financial Guidance
November 1, 2022 | finance.yahoo.com
Zacks.com featured highlights include Tandem Diabetes Care, Krispy Kreme, Caesars Entertainment and Vestas Wind Systems
October 26, 2022 | finance.yahoo.com
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings Expected to Decline
October 25, 2022 | nasdaq.com
Is It Time To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?
October 14, 2022 | finance.yahoo.com
What Does Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Share Price Indicate?
October 12, 2022 | markets.businessinsider.com
5 Analysts Have This to Say About Tandem Diabetes Care
October 12, 2022 | finance.yahoo.com
Got $1,000? These 3 Stocks Could Double Your Money in 5 Years.
October 11, 2022 | finance.yahoo.com
Tandem Diabetes Care, Inc. (TNDM)
October 4, 2022 | finance.yahoo.com
Tandem Diabetes Care to Announce Third Quarter 2022 Financial Results on November 2, 2022
October 4, 2022 | msn.com
Short Volatility Alert: Tandem Diabetes Care, Inc.
September 16, 2022 | finance.yahoo.com
Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues
September 14, 2022 | finance.yahoo.com
Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
September 10, 2022 | nasdaq.com
Recent gains in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) help add back some value on insider purchases worth US$511k, still down US$119k
September 7, 2022 | markets.businessinsider.com
Where Tandem Diabetes Care Stands With Analysts
September 5, 2022 | finance.yahoo.com
As Tandem Diabetes Care, Inc.'s market cap (NASDAQ:TNDM) drops to US$2.9b, insiders might be questioning their decision to buy earlier this year
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings
11/03/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
CUSIP
N/A
CIK
1438133
Web
www.tandemdiabetes.com
Phone
(858) 366-6900
Fax
N/A
Employees
2,000
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$76.93
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$43.00
Forecasted Upside/Downside
+84.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$15.57 million
Net Margins
-8.59%
Pretax Margin
-8.30%
Return on Equity
-8.34%
Return on Assets
-3.63%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
4.81
Quick Ratio
4.20

Sales & Book Value

Annual Sales
$702.80 million
Price / Sales
3.81
Cash Flow
$0.54 per share
Price / Cash Flow
77.12
Book Value
$6.56 per share
Price / Book
6.35

Miscellaneous

Outstanding Shares
64,300,000
Free Float
62,884,000
Market Cap
$2.68 billion
Optionable
Optionable
Beta
0.99

Social Links


Key Executives

  • Mr. John F. SheridanMr. John F. Sheridan (Age 67)
    Pres, CEO & Director
    Comp: $1.6M
  • Ms. Leigh A. VossellerMs. Leigh A. Vosseller (Age 49)
    Exec. VP, CFO & Treasurer
    Comp: $764.64k
  • Mr. David B. Berger Esq. (Age 52)
    Exec. VP & COO
    Comp: $765.11k
  • Ms. Susan M. MorrisonMs. Susan M. Morrison (Age 43)
    Exec. VP & Chief Admin. Officer
    Comp: $764.35k
  • Mr. Brian B. HansenMr. Brian B. Hansen (Age 54)
    Exec. VP & Chief Commercial Officer
    Comp: $781.22k
  • Ms. Elizabeth Anne GasserMs. Elizabeth Anne Gasser (Age 46)
    Exec. VP & Chief Strategy Officer
    Comp: $764.64k
  • Mr. Rick A. Carpenter (Age 59)
    Chief Technical Officer
  • Ms. Shannon M. Hansen (Age 56)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. Ross Sylvia
    VP of Marketing
  • Mr. Tom Fox
    Sr. VP of HR & Organizational Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TNDM shares.
View TNDM analyst ratings or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2023?

9 equities research analysts have issued 12 month target prices for Tandem Diabetes Care's shares. Their TNDM share price forecasts range from $43.00 to $130.00. On average, they expect the company's stock price to reach $76.93 in the next year. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2022?

Tandem Diabetes Care's stock was trading at $150.52 on January 1st, 2022. Since then, TNDM shares have decreased by 72.1% and is now trading at $42.05.
View the best growth stocks for 2022 here.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our TNDM earnings forecast.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) announced its earnings results on Wednesday, November, 3rd. The medical device company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.01. The medical device company had revenue of $179.63 million for the quarter, compared to analyst estimates of $172.80 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 8.34% and a negative net margin of 8.59%. During the same quarter in the prior year, the company earned ($0.09) earnings per share.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care's stock reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $800.00 million-$805.00 million, compared to the consensus revenue estimate of $836.40 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.63%), BlackRock Inc. (9.48%), State Street Corp (2.77%), Eminence Capital LP (2.47%), Bellevue Group AG (2.44%) and Stephens Investment Management Group LLC (1.52%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $42.05.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $2.70 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

The company employs 2,000 workers across the globe.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 12/1/2022 by MarketBeat.com Staff